# E7389 in Treating Patients With Advanced Solid Tumors

> **NCT00047034** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** eribulin mesylate
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00047034
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2013-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047034, "E7389 in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00047034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*